FDA Approves New Molecularly Targeted Therapeutic for Non-Hodgkin Lymphoma
The flurry of treatments approved by the U.S. Food and Drug Administration (FDA) for treating hematological malignancies continued last...
Category: Policy
The flurry of treatments approved by the U.S. Food and Drug Administration (FDA) for treating hematological malignancies continued last...
Today, the American Association for Cancer Research (AACR) released its seventh annual Cancer Progress Report. The report highlights how...
This week’s excitement surrounding the groundbreaking U.S. Food and Drug Administration (FDA) approval of the CAR T–cell therapy tisagenlecleucel...
Yesterday marked a much anticipated milestone for the oncology community: The U.S. Food and Drug Administration (FDA) announced the...
Patient enrollment in clinical trials has long been on the minds of oncologists and researchers. In 1990, fewer than...
Earlier this week, the U.S. Food and Drug Administration (FDA) approved a new molecularly targeted therapeutic called neratinib (Nerlynx)...
Hot on the heels of the FDA’s landmark approval of an anticancer therapeutic for use based on whether a...
The American Association for Cancer Research (AACR) has appeared in numerous publications lately, showcasing the breadth of our mission...
Tuesday marked a milestone for the oncology community: The U.S. Food and Drug Administration (FDA) announced its first approval...
At the end of last week, the U.S. Food and Drug Administration (FDA) approved expanding the use of pembrolizumab...